

10th International Oncolytic Virus Meeting, Vancouver, 2016

AGENDA

Saturday, October 1st (afternoon & evening)

3:00-8:00 pm Registration Open

6:00-8:00 pm Welcome reception

8:00-9:00 pm Keynote Talks

- Cassian Yee (MD Anderson): Adoptive T cell therapy (ACT)
- Yonghong Wan (McMaster University): Combining ACT and OVs

Sunday, October 2nd (morning)

8:00-8:45 am Breakfast

9:00-12:00 noon Session 1: Viral Engineering and Replication

- Chairs: David Stojdl/Len Seymour

9:00-9:20 am

Abstract #123: STRATEGIES TO ENHANCE BOTH ONCOLYTIC ACTIVITY AND SAFETY SIMULTANEOUSLY FOR ONCOLYTIC VIROTHERAPY – *William Jia (UBC)*

9:25-9:40 am

Abstract #87: Development of immunogenic BHV-1 to target non-inflamed tumors – *Karen Mossman (McMaster University)*

9:45-10:00 am

Abstract #59: A genome wide lentiviral CRISPR screen identifies genes & pathways that underlie resistance to oncolytic virus infection & killing - *Larissa Pikor (Ottawa Hospital Research Institute)*

10:05-10:20 am

Abstract #37: Oncolytic viruses targeting the RNAi pathway - *Amelia Aitken (Ottawa Hospital Research Institute)*

10:20-10:40 am Coffee Break

10:40-10:55 am

Abstract #96: Novel oHSV vectors designed to evade the innate immune system show increased therapeutic efficacy in glioblastoma mouse models - *Korneel Grauwet (Harvard Medical School)*

11:00-11:15 am

Abstract #117: Next Generation Oncolytic Vaccinia Viruses – *Andrea McCart (U of Toronto)*

11:20-11:35 am

Abstract #62: Characterizing the host mRNAs actively translated during viral oncolysis - *Huy-Dung Hoang (CHEO Research Institute, University of Ottawa)*

11:40-11:55 am

Abstract #78: Random mutagenesis of Vaccinia virus uncovers novel clinical candidate oncolytic backbones with unique phenotypes - *Brian Keller (OHRI)*

12:00-1:30 pm **Lunch (at leisure)**

Sunday, October 2nd (afternoon)

1:30-4:30 pm **Session 2: Oncolytic viruses and Immunity A**
▪ **Chairs: Brian Lichty/Nino Chiocca**

1:30-1:50 pm

Combining Immune Activation and Targeting Immunosuppression to Optimize Oncolytic Viral Activity - *Steve Thorne (U of Pittsburgh)*

1:55-2:15 pm

When an oncolytic vaccine, is actually an oncolytic vaccine - *Brian Lichty (McMaster University)*

2:20-2:40 pm

A clinical trial of viral vector-mediated immunogene therapy and immune checkpoint inhibition - *Nino Chiocca (Harvard Medical School)*

2:45-3:00 pm **Coffee Break**

3:00-3:15 pm

Abstract #53: Immune cell recruitment and anti-tumor IgG responses following intrapleural administration of oHSV Seprehvir in patients with mesothelioma - *Joe Conner (Virttu Biologics)*

3:20-3:35 pm

Abstract #66: Oncolytic virus-mediated immunotherapy - *Marie-Claude Bourgeois-Daigneault (Ottawa Hospital Research Institute)*

3:40-3:55 pm

Abstract #44: Oncolytic adenovirus coated with MHC I-restricted peptides for simultaneous targeting of several (neo-) antigens to counteract tumor immune escape - *Siri Tähtinen (University of Helsinki)*

4:00-4:15 pm

Abstract #101: Complete remission of breast cancer tumors in an immune competent mouse model using measles and VSV-measles chimeric viruses - *Christopher Richardson (Dalhousie University)*

Sunday, October 2nd (evening)

4:30-5:30 pm **Working Dinner**

5:30-7:30 pm **Session 3: Combination Therapies A**

▪ **Chairs: Jean-Simon Diallo/Caroline Breitbach**

Monday, October 3rd (afternoon)

1:30-4:30 pm Session 5: Oncolytic viruses and Immunity B
▪ **Chairs: Alan Melcher/Brian Lichty**

1:30-1:50 pm

Intravenous Delivery of Oncolytic Reovirus to Brain Tumours in Patients to Immunologically Prime Tumours for Sequential Checkpoint Blockade - *Alan Melcher (ICR, London)*

1:55-2:15 pm

Antibody-mediated delivery of oncolytic viruses to tumours via monocyte carriage – *Elizabeth Ilett (U of Leeds)*

2:20-2:35 pm

Abstract #29: Determinants of efficacy in virotherapy - *Ruta Veinalde (NCT Heidelberg)*

2:40-3:00 pm

Coffee Break

3:00-3:15 pm

Abstract #33: OV sensitize tumor cells for NYESO-1 recognition - *Tiphaine Delaunay (INSERM)*

3:20-3:35 pm

Abstract #92: Blockade of PD-1 or TIM3 on Acutely Expanding CD8+ Effector T Cell Populations Following VSV Virotherapy Has Minimal Effects on Enhancing Therapy - *Richard Vile (Mayo Clinic)*

3:40-3:55 pm

Abstract #82: Arming a HSV-2- based oncolytic virus with the ability to re-direct hosts innate immune cells to attack tumor cells - *Shaun Xiaoliu Zhang (University of Houston)*

4:00-4:15 pm

Abstract #90: Eradication of peritoneal carcinomatosis using a Maraba virus infected cell vaccine expressing IL-12 requires recruitment of Natural Killer cells - *Almohanad Alkayyal (Ottawa Hospital Research Institute)*

Monday, October 3rd (evening)

4:30-5:30 pm Working Dinner

5:30-7:30 pm Session 6: Tumour Microenvironment

▪ **Chairs: Martine Lamfers/John Bell**

5:30-5:50 pm

John Bell -TBA

5:55-6:15 pm

Oncolytic viral therapy with Delta24-RGD can induce tumor-detrimental environment via phenotypic shift of macrophages - *Wouter van den Bossche (Dep of Neurosurgery/ Dep of Immunology, Erasmus MC)*

6:20-6:35 pm

Abstract #130: A novel T cell exhausted murine glioma model for OV therapeutic strategy - *Hiroshi Nakashima (Harvard)*

6:40-6:55 pm

Abstract #142: Oncolytic adenovirus targeting tumour cells and stromal components - *Joshua Freedman (U of Oxford)*

7:00-7:15 pm

Abstract #30: Predictive gene expression signature for personalized medicine – *Amber Miller (May Clinic)*

7:20-7:35 pm

Abstract #72: Phase II CALM Extension study: Intratumoral Coxsackievirus A21 increases immune-cell infiltrates and up-regulates immune-checkpoint molecules in the microenvironment - *Darren Shafren (Viralytics)*

8:00-10:00 pm **Poster Session #2 (MacKenzie Ballroom)**

Tuesday, October 4th (morning)

8:00-8:45 am **Breakfast**

9:00-12:00 noon **Session 7: Combination Therapies B**

▪ **Chairs: Kah-Whye Peng/Nori Kasahara**

9:00-9:20 am

Jean-Simon Diallo (Ottawa Hospital Research Institute) - TBA

9:25-9:40 am

Abstract #74: Multiple Mechanisms of Oncolytic Herpes Simplex Virus and Aurora A Kinase Inhibition in Models of Neuroblastoma and Malignant Peripheral Nerve Sheath - *Leslee Sprague (Ohio State)*

9:45-10:00 am

Abstract #135: Cooperation Between Endogenous Lymphocytes and ACT - *Boris Simovic (McMaster University)*

10:05-10:25 am

Coffee Break

10:25-10:40 am

Abstract #126: MEK kinase inhibitor, Trametinib, Suppresses Macrophage-Secreted TNF- α on Oncolytic HSV-1 Therapy, Enhancing Virotherapy - *Ji Young Yoo (Ohio State)*

10:45-11:00 am

Abstract #73: Viro-immunotherapy with oncolytic parvovirus H-1 in combination with bevacicumab and PD-1 checkpoint blockade leads to rapid anti-tumor response in three subsequent cases of patients with recurrent glioblastoma
– *Karsten Galetneky (Klinikum Darmstadt)*

12:00-1:00 pm **LUNCH (at leisure)**

Tuesday, October 4th (afternoon)

1:00-4:00 pm **Session 8: Clinical Trials**

▪ **Chairs: Robert Coffin/Steven Russell**

1:00-1:20 pm

Abstract #40: Updated phase 1b analysis of MASTERKEY-265, a phase 1b/3 study of talimogene laherparepvec and pembrolizumab for unresectable stage IIIB-IV melanoma - *Robert H.I. Andtbacka - (Huntsman Cancer Institute, University of Utah)*

1:25-1:45 pm

Measles as a versatile oncolytic agent - *Steven Russell (Mayo Clinic)*

1:50-2:05 pm

Abstract #120: A Phase 2 trial to evaluate efficacy and safety of HF10 oncolytic virus immunotherapy and ipi in pts with unresectable or metastatic melanoma - *Robert H.I. Andtbacka – (Huntsman Cancer Institute, University of Utah)*

2:10-2:25 pm

Abstract #51 Oncolytic H-1 parvovirus shows safety and surrogate efficacy in a phase I/IIa clinical trial (ParvOryx01) for recurrent glioblastoma patients - *Jean Rommelaere (Deutsches Krebsforschungszentrum, Heidelberg)*

2:30-2:45 pm

Abstract #71 Molecular Analyses and Immune Activity of Toca 511 a Retroviral Replicating Vector in Preclinical Models and Three Ascending Dose Trials in Patients w - *Douglas Jolly (Tocagen Inc.)*

2:50-3:05 pm

Coffee Break

3:05-3:20 pm

Abstract #89 Phase I/II CANON study: Oncolytic immunotherapy for the treatment of Non-Muscle Invasive Bladder (NMIBC) Cancer using Intravesical Coxsackievirus A21 - *Hardev Pandha (U of Surrey)*

3:25-3:40 pm

Abstract #102 Phase 1 Study of ITu Seprehvir (oHSV) in Children and Young Adults Demonstrates Safety and Induces Both an Inflammatory Reaction and Delayed Viremia - *Keri Streby (Nationwide Children's Hospital)*

Tuesday, October 4th (evening)

6:00-6:30 pm **Reception**

6:30-TBA **Banquet**